ChemicalBook
Chinese Japanese Germany

Everolimus

Overview Indications Mode of action Adverse reactions Warning and precautions References
Everolimus
Everolimus
CAS No.
159351-69-6
Chemical Name:
Everolimus
Synonyms
SDZRAD;RAD-001;Certica;Certican;Afinitor;Zortress;Everolimus;CERTICAN(R);EveroliMus API;Everolimus, >=98%
CBNumber:
CB9502411
Molecular Formula:
C53H83NO14
Formula Weight:
958.232
MOL File:
159351-69-6.mol

Everolimus Properties

Melting point:
NA
Flash point:
2℃
storage temp. 
−20°C
Water Solubility 
Soluble in dimethysulfoxide,ethanol and chloroform. Slightly soluble in water.
Stability:
Hygroscopic
SAFETY
  • Risk and Safety Statements
  • Hazard and Precautionary Statements (GHS)
Hazard Codes  T,Xn,F
Risk Statements  48/25-36-20/21/22-11
Safety Statements  45-36/37-26-16
RIDADR  UN 1648 3 / PGII
WGK Germany  2
10
Symbol(GHS):
Signal word: Danger
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H225 Highly Flammable liquid and vapour Flammable liquids Category 2 Danger P210,P233, P240, P241, P242, P243,P280, P303+ P361+P353, P370+P378,P403+P235, P501
H319 Causes serious eye irritation Serious eye damage/eye irritation Category 2A Warning P264, P280, P305+P351+P338,P337+P313P
H372 Causes damage to organs through prolonged or repeated exposure Specific target organ toxicity, repeated exposure Category 1 Danger P260, P264, P270, P314, P501
Precautionary statements:
P210 Keep away from heat/sparks/open flames/hot surfaces. — No smoking.
P260 Do not breathe dust/fume/gas/mist/vapours/spray.
P264 Wash hands thoroughly after handling.
P264 Wash skin thouroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P314 Get medical advice/attention if you feel unwell.
P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

Everolimus price More Price(7)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich E-068 Everolimus solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material 159351-69-6 068-1ml $207 2018-11-13 Buy
Alfa Aesar J60139 Everolimus 159351-69-6 10mg $207 2018-11-13 Buy
Alfa Aesar J60139 Everolimus 159351-69-6 5mg $140 2018-11-13 Buy
Cayman Chemical 11597 Everolimus ≥98% 159351-69-6 5mg $65 2018-11-13 Buy
Cayman Chemical 11597 Everolimus ≥98% 159351-69-6 10mg $98 2018-11-13 Buy

Everolimus Chemical Properties,Uses,Production

Overview

Everolimus is a derivative of Rapamycin(sirolimus), and works similarly to Rapamycin as an mTOR(mammalian target of rapamycin) inhibitor[1-3]. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors, Everolimus takes effect solely on the mTORC1 protein and not on the mTORC2 protein[1]. In transplantation medicine, it is marketed under the trade names Zortress(USA) and Certican(Europe)[4]. It has been also used for the treatment of tumors, being marketed as Afinitor(general tumours) and Votubia(tumours as a result of TSC) in oncology[5, 6].

Indications

Everolimus is indicated for the treatment of numerous diseases and disorders. It indicated for the treatment of the following cases including both tumors and organ transplantation:
Patients with advance kidney cancer[7];
Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer(advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole[8-10];
Adult patients with progressive neuroendocrine tumors of pancreatic origin(PNET) with unresectable, locally advanced or metastatic disease[9, 10];
Adult patients with advanced renal cell carcinoma(RCC) after failure of treatment with sunitinib or sorafenib;
Adult patients with renal angiomyolipoma and tuberous sclerosis complex(TSC), not requiring immediate surgery[11];
Pediatric and adult patients with tuberous sclerosis complex(TSC) for the treatment of subependymal giant cell astrocytoma(SEGA) that requires therapeutic intervention but cannot be curatively resected[12];
Adult and pediatric patients aged 2 years and older with Tuberous Sclerosis Complex(TSC)-associated partial-onset seizures[10];
Preventing the organ rejection during/after renal and liver transplantation[14, 15];
Progressive, well-differentiated non-functional, neuroendocrine tumors[NET] of gastrointestinal(GI) or lung origin with unresectable, locally advanced or metastatic disease[16].

Mode of action

The mammalian target of rapamycin(mTOR) pathway is one of the most clinically important molecular signalling networks to emerge over the past decade. It is the protein kinase at the core of this intricate and continually evolving pathway, controls cellular growth and behavior, impacting vital processes from immune reactivity to cancer progression[17, 18]. Everolimus is an mTOR inhibitor that binds with high affinity to the FK506 binding protein-12(FKBP-12), thereby forming a drug complex that inhibits the activation of mTOR[19-20]. This inhibition reduces the activity of effectors downstream, which leads to a blockage in the progression of cells from G1 into S phase, and subsequently inducing cell growth arrest and apoptosis. Everolimus also inhibits the expression of hypoxia-inducible factor, leading to a decrease in the expression of vascular endothelial growth factor[19, 20]. The result of everolimus inhibition of mTOR is a reduction in cell proliferation, angiogenesis, and glucose uptake. Since highly expression of mTOR is an important factor that promoting the cancer, blocking mTOR by Everolimus can effectively treat some kinds of cancer and the organ rejection due to immune response during/after organ transplantation[21, 22].

Adverse reactions

Some serious adverse reactions associated with Everolimus include non-infection pneumonitis, infections, severe hypersensitivity reactions, angioedema with concomitant use of ACE inhibitors, stomatitis, renal failure, impaired wound healing, metabolic disorders and myelosuppression[10]. Various common side effects include Bloating or swelling of the face, arms, hands, lower legs, or fee bloody nose, chest pain or tightness, chills, cough, decreased weight, diarrhea, difficult or labored breathing, difficulty with swallowing, fever, general feeling of discomfort or illness, hoarseness, lower back or side pain, painful or difficult urination, rapid weight gain, sores, ulcers, or white spots on the lips, tongue, or inside the mouth and tingling of the hands or feet[23]. Less common side effects include bleeding gums, bloody urine, blurred vision, burning, crawling, itching, numbness, prickling, or tingling feelings, coughing up blood, extreme tiredness or weakness, fast, pounding, or irregular heartbeat or pulse, increased thirst or urination, irregular breathing, loss of appetite, nausea, nervousness, nosebleeds, prolonged bleeding from cuts, red or black, tarry stools, red or dark brown urine, slow heartbeat, stomach ache, sweating, unusual tiredness or weakness and vomiting[23].

Warning and precautions

People who are allergic to Everolimus should be disabled. Since it can increase your risk of serious infections or getting certain cancers, such as lymphoma or skin cancer. The patients should ask their doctor about the specific risk[10, 23].
Patients who have the following conditions should consult for doctor for advice before administration: problem in digesting lactose or galactose(sugar); high cholesterol or triglycerides; liver disease; a heart transplantation; or skin cancer in them or their family members[23].
Since it may harm the unborn baby as well as affect fertility(the capability to have children), women should take effective birth control during administration of Everolimus and for at least eight weeks after stopping drugs. Should consult the doctor for advice if you want to or has become pregnant. It may also affect the fertility of men as well. It is generally not recommended to have breast-feed during the administration of Everolimus for women[10, 23].

References

  1. https://www.drugbank.ca/drugs/DB01590
  2. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm488028.htm
  3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022334s036lbl.pdf
  4. Junge, G., et al. "EVEROLIMUS, MTORC1 INHIBITION, AND IMPACT ON HEPATOCELLULAR CARCINOMA RECURRENCE AFTER LIVER TRANSPLANTATION-12, 24, AND 36 MONTHS DATA FROM 719 LTX RECIPIENTS." Transplant International 27(2014]: 23-23.
  5. Yao, J. C., et al. "Everolimus for advanced pancreatic neuroendocrine tumors. " New England Journal of Medicine 364.6(2011]: 514-23.
  6. Motzer, Robert J, et al. "Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma." Lancet Oncology 17.7(2016]: 917-927.
  7. Nachtnebel, A. "Everolimus[Afinitor] for advanced/metastatic kidney cancer."[2009].
  8. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm254350.htm
  9. https://www.reuters.com/article/2012/07/20/novartis-afinitor-idUSL2E8IKD8B20120720
  10. https://www.rxlist.com/afinitor-drug.htm#indications_dosage
  11. Matin, Surena F. "Everolimus for the treatment of TSC-associated tumors." Community Oncology 9.12(2012]:361–362.
  12. Cappellano, A. M., et al. "Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex." Childs Nervous System Chns Official Journal of the International Society for Pediatric Neurosurgery 29.12(2013]:2301-2305.
  13. Bilbao, Itxarone, et al. "Multiple indications for everolimus after liver transplantation in current clinical practice." World Journal of Transplantation 4.2(2014]: 122-132.
  14. Ganschow, Rainer, et al. "The role of everolimus in liver transplantation." Clinical & Experimental Gastroenterology 7.default(2014]:329-343.
  15. Dunn, C, and K. F. Croom. "Everolimus: a review of its use in renal and cardiac transplantation. " Drugs 66.4(2006]:547-570.
  16. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm488028.htm
  17. Geissler, Edward K., H. J. Schlitt, and G. Thomas. "mTOR, Cancer and Transplantation." American Journal of Transplantation 8.11(2010]:2212-2218.
  18. Young, D. A., and C. L. Nickersonnutter. "mTOR--beyond transplantation. " Current Opinion in Pharmacology 5.4(2005]: 418-423.
  19. Anandappa, G., A. Hollingdale, and T. Eisen. "Everolimus – a new approach in the treatment of renal cell carcinoma." Cancer Management & Research 2.1(2010]:61.
  20. Raimondo, L., et al. "Everolimus induces Met inactivation by disrupting the FKBP12/Met complex:" Oncotarget 7.26(2016]:40073-40084.
  21. Sabatini, David M. "mTOR and cancer: insights into a complex relationship." Nature Reviews Cancer 6.9(2006]:729.
  22. Efeyan, Alejo, and D. M. Sabatini. "mTOR and cancer: many loops in one pathway." Current Opinion in Cell Biology 22.2(2010]:169-176.
  23. https://www.drugs.com/mtm/everolimus.html

Chemical Properties

Off White Solid

Uses

Macrolide immunosuppressant; derivative of Rapamycin. Inhibits cytokine-mediated lymphocyte proliferation

Uses

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM

Uses

Everolimus Macrolide immunosuppressant; Everolimus is a derivative of Rapamycin. Everolimus inhibits cytokine-mediated lymphocyte proliferation.

Uses

Everolimus is a semi-synthetic macrocyclic lactone prepared from rapamycin by selective alkylation of the 42-hydroxy group with a silyl-protected hydroxyethyl triflate moiety, followed by addition of an ethylhydroxy moiety to provide greater stability and bioavailability. Like all tacrolimus analogues, everolimus binds to receptor protein, FKBP12. The complex then binds to mTOR preventing it from interacting with target proteins. Everolimus is extensively cited in the literature with over 2,000 citations.

Definition

ChEBI: A macrocyclic lactone that is rapamycin in which the hydroxy group attached to the cyclohexyl moiety has been converted to the corresponding 2-hydroxyethyl ether. It is an immunosuppressant and antineoplastic agent.

Everolimus Preparation Products And Raw materials

Raw materials

Preparation Products


Everolimus Suppliers

Global( 227)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
TianYuan Pharmaceutical CO.,LTD
+86-755-23284190 13684996853
+86-755-23284190 sales@tianpharm.com CHINA 312 58
Capot Chemical Co.,Ltd.
+86 (0)571-855 867 18
+86 (0)571-858 647 95 sales@capotchem.com China 19958 60
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 22080 58
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 sales01@cooperate-pharm.com CHINA 1529 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 20795 55
Shanghai Yingrui Biopharma Co., Ltd.
+86-21-33585366 E-mail:sales03@shyrchem.com
+86-21-34979012 sales03@shyrchem.com CHINA 663 60
Hubei XinRunde Chemical Co., Ltd.
+8615102730682; +8618874586545
bruce@xrdchem.cn CHINA 551 55
ATK CHEMICAL COMPANY LIMITED
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 ivan@atkchemical.com CHINA 10714 60
Shanghai Arbor Chemical Co., Ltd.
021-60451682
021-60451683 act@arborchemical.com CHINA 905 58
Zhejiang ZETian Fine Chemicals Co. LTD
+86-18957127338
sales@zetchem.com CHINA 1258 58

View Lastest Price from Everolimus manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2018-03-29 Everolimus 159351-69-6
159351-69-6
US $10.00 / KG 10G 99% 10mt Hubei XinRunde Chemical Co., Ltd
2018-08-08 Everolimus
159351-69-6
US $1.00 / KG 1KG 99% 1000kg

159351-69-6(Everolimus)Related Search:


Copyright 2017 © ChemicalBook. All rights reserved